Findings

What do systematic reviews say?

276 questions · 290 findings · 42 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 26 · 9%GRADE not reported 17 · 5.9%Very low 82 · 28.3%Low 92 · 31.7%Moderate 66 · 22.8%High 7 · 2.4%

Selective serotonin reuptake inhibitors vs placebo

PSG sleep outcomes (at 12 weeks) · adults with insomnia

1 finding from 1 review

Antidepressants for insomnia in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 60 participants
Very low

Autologous non‐myeloablative selective HSCT vs cyclophosphamide

Overall mortality · people with systemic sclerosis

Autologous non‐myeloablative selective HSCT showed no clear difference in overall mortality compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
RR 0.9 [0.44, 1.85]
1 study · 156 participants
Moderate

Autologous non‐myeloablative selective HSCT vs cyclophosphamide

Event‐free survival · people with systemic sclerosis

Autologous non‐myeloablative selective HSCT probably leads to lower event‐free survival compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
HR 0.34 [0.16, 0.74]
1 study · 156 participants
Moderate

Autologous non‐myeloablative selective HSCT vs cyclophosphamide

Functional ability · people with systemic sclerosis

1 finding from 1 review

Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 131 participants
Low

Autologous non‐myeloablative selective HSCT vs cyclophosphamide

Skin thickness – mRSS Scale 0–51 in which a higher number is worse skin thickening · people with systemic sclerosis

1 finding from 1 review

Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 131 participants
Moderate

Autologous non‐myeloablative selective HSCT vs cyclophosphamide

Interstitial lung disease – FVC % predicted A lower percentage represents worse lung disease · people with systemic sclerosis

1 finding from 1 review

Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 131 participants
Moderate

Autologous non‐myeloablative selective HSCT vs cyclophosphamide

Pulmonary arterial hypertension · people with systemic sclerosis

The review found no eligible studies for this question.

1 finding from 1 review

Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Autologous non‐myeloablative selective HSCT vs cyclophosphamide

Serious adverse events · people with systemic sclerosis

Autologous non‐myeloablative selective HSCT probably leads to higher serious adverse events compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
RR 1.7 [1.2, 2.3]
1 study · 156 participants
Moderate

Selective serotonin reuptake inhibitors vs atypical agent

Improvement in depression at 6‐12 weeks: HAM‐D score (continuous) · adults living with HIV and depression

1 finding from 1 review

Antidepressants for depression in adults with HIV infection 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 70 participants
Low

Selective serotonin reuptake inhibitors vs atypical agent

Improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) · adults living with HIV and depression

Selective serotonin reuptake inhibitor (SSRI) showed no clear difference in improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) compared with atypical agent (low certainty).

1 finding from 1 review

Antidepressants for depression in adults with HIV infection 2018 · Cochrane Headline outcomes only
RR 0.94 [0.79, 1.11]
1 study · 70 participants
Low

Selective serotonin reuptake inhibitors vs atypical agent

Improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) · adults living with HIV and depression

Selective serotonin reuptake inhibitor (SSRI) showed no clear difference in improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) compared with atypical agent (low certainty).

1 finding from 1 review

Antidepressants for depression in adults with HIV infection 2018 · Cochrane Headline outcomes only
RR 0.78 [0.52, 1.17]
1 study · 70 participants
Low

Selective serotonin reuptake inhibitors vs atypical agent

Dropout · adults living with HIV and depression

Selective serotonin reuptake inhibitor (SSRI) showed no clear difference in study dropouts at 6‐12 weeks compared with atypical agent (low certainty).

1 finding from 1 review

Antidepressants for depression in adults with HIV infection 2018 · Cochrane Headline outcomes only
RR 1.67 [0.43, 6.45]
1 study · 70 participants
Low

Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)

Dropout · adults living with HIV and depression

It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes study dropouts at 6‐12 weeks compared with tricyclic antidepressant (TCA) (very low certainty).

1 finding from 1 review

Antidepressants for depression in adults with HIV infection 2018 · Cochrane Headline outcomes only
RR 0.81 [0.51, 1.3]
2 studies · 64 participants
Very low

Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)

Adverse effects during antidepressant treatment period (0‐12 weeks) · adults living with HIV and depression

It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes adverse effects during antidepressant treatment period (0‐12 weeks) compared with tricyclic antidepressant (TCA) (very low certainty).

1 finding from 1 review

Antidepressants for depression in adults with HIV infection 2018 · Cochrane Headline outcomes only
RR 1.05 [0.67, 1.64]
1 study · 14 participants
Very low

Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)

Improvement in depression at 6‐12 weeks: HAM‐D score (continuous) · adults living with HIV and depression

1 finding from 1 review

Antidepressants for depression in adults with HIV infection 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 14 participants
Very low

Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)

Improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) · adults living with HIV and depression

It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) compared with tricyclic antidepressant (TCA) (very low certainty).

1 finding from 1 review

Antidepressants for depression in adults with HIV infection 2018 · Cochrane Headline outcomes only
RR 0.89 [0.54, 1.46]
2 studies · 64 participants
Very low

Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)

Improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) · adults living with HIV and depression

It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) compared with tricyclic antidepressant (TCA) (very low certainty).

1 finding from 1 review

Antidepressants for depression in adults with HIV infection 2018 · Cochrane Headline outcomes only
RR 1.24 [0.68, 2.24]
2 studies · 64 participants
Very low

Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)

Efficacy as a continuous outcome · patients with cancer and depression

1 finding from 1 review

Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 237 participants
Very low

Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)

Efficacy as a dichotomous outcome · patients with cancer and depression

It is very uncertain whether selective serotonin reuptake inhibitors (SSRIs) changes efficacy as a dichotomous outcome compared with tricyclic antidepressants (TCAs) (very low certainty).

1 finding from 1 review

Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes only
RR 1.1
2 studies · 199 participants
Very low

Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)

Acceptability ‐ total dropouts · patients with cancer and depression

It is very uncertain whether selective serotonin reuptake inhibitors (SSRIs) changes dropouts due to any cause (acceptability) compared with tricyclic antidepressants (TCAs) (very low certainty).

1 finding from 1 review

Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes only
RR 0.83 [0.53, 1.3]
3 studies · 237 participants
Very low